Research Antibodies Size to Surpass Around US$ 16.5 Billion by 2030

Published: Sep 27, 2022

The global Research Antibodies market size is expected to surpass around US$ 16.5 billion by 2030, according to a new report by Vision Research Reports.

The global Research Antibodies market size was valued at US$ 13.4 billion in 2019 and is anticipated to grow at a CAGR of 12.2 % during forecast period 2020 to 2030.

Antibodies are proteins made by B cells and are a part of the human body’s immune system. These molecules have the ability to bind themselves to specific molecules that make them an ideal probe for cell research purposes. They are also used to isolate and aid in the identification of molecules of interest in cells. Currently, antibodies are one of the most important tools to study the function of a protein in cells.

Key Insights

The primary antibodies segment captured the largest revenue share of over 75.06% in 2021 and is also projected to grow at the fastest rate throughout the forecast period.
The monoclonal antibodies segment accounted for a dominant share of over 60.2% in 2021.
The western blotting segment accounted for a dominant share of over 25.05% in 2021.
In 2021, the rabbit segment held the largest share of over 45.2%.
The oncology segment accounted for the largest share of over 30.5% in 2021.
The academic and research institutions segment captured the largest revenue share of over 60.06% in 2021 and is projected to grow at the fastest rate throughout the forecast period.
North America dominated the market in 2021 with a revenue share of over 35.21%.

Immediate Delivery Available | Get the sample copy of report@ https://www.visionresearchreports.com/report/sample/35364

Growth Factors

Major market drivers include rise in R&D initiatives undertaken by biopharmaceutical and biotechnology companies and government bodies, growing interest in the study of neurobiology and stem cell, availability of technologically advanced products, and strategic collaborations among various market players and academic research organizations.

Increase in the usage of research antibodies to develop treatment options for various diseases is also expected to boost market growth during the forecast period.

Additionally, rise in funds invested by pharmaceutical and biotechnology companies to enhance the study of proteomics and genomics is expected to drive the market

North America dominated the research antibodies market in owing to increasing focus on R&D in the fields of biomedicine, stem cell, and cancer.

Scope of the Report

Report Coverage	Details
Market Size in 2019	USD 13.4 Billion
Revenue Forecast by 2030	USD 16.5 Billion
CAGR	12.2%

Report Highlights

By product, primary antibodies held the dominant share in 2019 in terms of revenue owing to greater specificity, therefore leading to increased adoption in R&D activities
Based on type, monoclonal antibodies captured a substantial market share in 2019 as they offer higher sensitivity for detection of antigens and also showcase efficient staining properties for various applications
The Western blotting technology segment has witnessed exponential growth owing to increasing prevalence of diseases with limited treatment options and rise in R&D activities conducted by pharmaceutical and biotechnology companies and academic institutes

Product Insights

The primary antibodies segment captured the largest revenue share of over 75.06% in 2021 and is also projected to grow at the fastest rate throughout the forecast period. This can be attributed to the increasing availability of primary antibodies using rabbits, mice, goats, and other species as hosts and the wide range of utility offered by such antibodies for applications in the R&D space. Also, owing to the usage of primary antibodies for frequently performed laboratory procedures, such as staining and imaging, the segment is predicted to grow at an exponential rate.

The secondary antibodies segment is expected to grow at a constant rate as these antibodies are more convenient and cost-effective to develop. Demand for secondary research antibodies is also anticipated to increase due to the availability of ready-to-use conjugated antibodies that can improve product development activities by assisting in the identification, grouping, and purification of targeted antigens. For instance, Thermo Fisher Scientific, Inc. provides fluorescent dye-conjugated secondary antibodies that make it easier to identify proteins in a variety of applications, including immunohistochemistry, western blotting, and fluorescent cell imaging.

Immediate Delivery Available | Buy this Premium Research Report@ https://www.visionresearchreports.com/report/cart/35364

Type Insights

The monoclonal antibodies segment accounted for a dominant share of over 60.2% in 2021 due to a sharp increase in the number of cancer research projects that demand high specificity antibodies. As monoclonal antibodies can efficiently adhere to or block antigens on cancer cells, these are employed in the identification and development of new medicines for various cancer types. This factor is expected to expand the growth prospects for the segment in the near future.

Polyclonal antibodies are projected to grow over the forecast period as these antibody structures are essential for the research aspects focusing on the purification of antigens and examination of histopathological tissue. Furthermore, polyclonal antibodies provide benefits like stability, practical storage methods, strong affinity, and excellent compatibility for ELISA and western blotting technologies, thereby propelling market growth.

Technology Insights

The western blotting segment accounted for a dominant share of over 25.05% in 2021 due to the widespread availability and adoption of the technique. In addition, due to the increased accuracy that the western blotting technique offers, it is typically chosen over alternative technologies for applications involving the detection of important protein entities. These attributes are expected to positively affect the segment growth.

Immunohistochemistry accounted for the second-largest share in 2021. The segment is anticipated to expand steadily due to its significant applications in the detection of enzymes, antigens, tumor suppressor genes, and tumor cell growth for cell-based research. Additionally, rising R&D spending and a high level of scientific awareness regarding the technique have led to increasing growth prospects for immunohistochemistry. Furthermore, benefits provided by the technique such as high sensitivity and simplicity of use are some of the factors anticipated to drive the market.

Source Insights

In 2021, the rabbit segment held the largest share of over 45.2%. Rabbits are extensively used for antibody production owing to several advantages such as higher affinity antibodies provided by rabbits as compared to those obtained from other animal hosts. Furthermore, the higher specificity provided by these antibodies makes them ideal for the detection of small molecules, hormones, toxins, and other biologically important substances.

The mouse segment is anticipated to witness considerable growth over the forecast period. Mice have been predominantly used in the production of antibodies due to their high reproduction rate and smaller size. Furthermore, the main factor influencing their widespread use is the structural similarity between mouse and human antibodies, which can significantly drive their adoption for R&D applications.

Application Insights

The oncology segment accounted for the largest share of over 30.5% in 2021 owing to a rise in the prevalence of cancer in key geographies. According to the American Cancer Society, in 2021, over 1.9 million new cancer cases were recorded in the U.S. Additionally, over 608,570 cancer deaths were also recorded in the same year in the U.S. As a result, more research antibodies will likely be used for designing and evaluating of new diagnostic and therapeutic approaches for the mitigation of cancer.

The stem cells segment is expected to witness significant growth owing to an increase in the number of stem cell research activities globally. The growth is also attributed to an increase in the adoption of stem cells for the treatment of a wide range of chronic ailments such as diabetes, cancer, Alzheimer’s, Parkinson’s, rheumatoid arthritis, and kidney and lung diseases. Furthermore, antibodies are used for stem cell research areas that include disease modeling, developmental biology, drug screening, reprogramming techniques development, and cell therapy that can positively affect market growth.

End-use Insights

The academic and research institutions segment captured the largest revenue share of over 60.06% in 2021 and is projected to grow at the fastest rate throughout the forecast period. This can be attributed to the increase in scientific initiatives by such centers for the development of novel therapies and tests for chronic diseases. For instance, in January 2021, researchers at The University of Texas Medical Branch at Galveston (UTMB Health) and The University of Texas Health Science Center at Houston (UTHealth) discovered two novel antibodies CoV2-06 and CoV2-14 for a potential novel antibody therapy for COVID-19 infection. Such initiatives can positively affect segment growth in the near future.

Pharmaceutical and biotechnology companies are expected to grow at a significant rate over the forecast period due to the increase in R&D activities in the life sciences domain. Furthermore, the increasing importance of antibodies for the development of novel biologic products and rising demand for quality control applications for various techniques, such as PCR and electrophoresis, are likely to boost segment growth.

Regional Insights

North America dominated the market in 2021 with a revenue share of over 35.21%. Growing focus on biomedical, stem cells and cancer research is a major contributor to the industry's growth. The regional growth is also favored by the presence of key players such as Thermo Fisher Scientific, Inc. and PerkinElmer, Inc. There is also an increasing number of biotechnology and biopharmaceutical firms in the region that are focusing on life sciences innovations, which is expected to fuel the industry expansion.

The market in Asia Pacific is expected to grow at the fastest rate over the forecast period as a result of an increase in collaborative activities carried out by academic institutions. For instance, in June 2019, scientists from Tsinghua University, China Medical University, and the Vaccine Research Center at the NIH started a research study on the identification and characterization of HIV-1 strains and their robust and widespread resistance to a variety of neutralizing antibodies. The National Natural Science Foundation Award, China's Ministry of Science and Technology, and Gates Foundation Grand Challenges China all supported this project. As a result, such government-funded scientific activities in the region are anticipated to drive the market.

Key Players

Abcam Plc; Bio-Rad Laboratories Inc.; PerkinElmer, Inc.; Agilent Technologies; Roche; Cell Signalling Technology, Inc.; Thermo Fisher Scientific; Lonza Group; and BD.

Market Segmentation

Research Antibodies Product Outlook